DDMAC to get upgrade in reorg

Share this article:

DDMAC is being upgraded from a division to an office, an FDA official said yesterday.

Rachel Behrman, deputy director of FDA's Office of Medical Policy, announced a restructure of the unit that would consist of an office with two divisions. What's the difference? Basically, it's a step up in the agency's org chart.

“An office may consist of several divisions,” explained an agency spokeswoman. “These divisions report to the office heads.”

Details are still being worked out, but the general idea is that the office would hold a division handling the review of healthcare professional-directed materials and one handling the review of DTC advertising.

The unit would continue to be housed within the Office of Medical Policy and would be named the Office of Prescription Drug Promotion, DDMAC director Tom Abrams told Peter Pitts of Porter Novelli and the Center for Medicine in the Public Interest.

The move reflects an increased emphasis on policing promotion from agency brass as well as the growth of the division in recent years. DDMAC has been adding staff as the agency struggles to keep up with a flood of promotional materials submitted.

In April, the division added a third DTC review group, headed by Sangeeta Vaswani and covering consumer promotions for products in the oncology biologics, pulmonary and allergy, psychiatry and anesthetics, analgesics and rheumatology categories. A fourth DTC review group is planned as well.


Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.